Skip to main content
    H

    Harmony Biosciences Holdings (HRMY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.96
    -0.80 (-2.37%)

    Market Cap: $1.98B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Harmony Biosciences Holdings (HRMY) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Harmony Biosciences Holdings reported revenue of $868.45M for the fiscal year ended Dec 31, 2025, up 21.5% from the year before. That year, net income was $158.69M with a net margin of 18.3%, operating cash flow was $348.20M and free cash flow was $347.89M. The quarter ended Sep 30, 2026 had revenue of $268.92M and net income of $48.20M.

    Revenue and Margins

    The operating margin was 24.0% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $6.00M, a compound annual rate of 129.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$868.45M+21.5%77.2%24.0%18.3%
    Dec 2024$714.73M+22.8%78.1%26.7%20.4%
    Dec 2023$582.02M+32.9%79.2%33.0%22.1%
    Dec 2022$437.86M+43.4%80.9%27.4%41.4%
    Dec 2021$305.44M+91.2%81.8%28.7%11.3%
    Dec 2020$159.74M+2564.6%82.6%10.6%-23.1%
    Dec 2019$6.00MN/A73.7%-2433.8%-2535.1%
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 9.1% from the year before. In the quarter ended Sep 2026, net income fell 5.2% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$868.45M$714.73M$582.02M$437.86M$305.44M$159.74M$6.00M$0
    Cost of revenue$198.34M$156.81M$121.24M$83.48M$55.52M$27.74M$1.58M$184.00K
    Gross profit$670.11M$557.92M$460.79M$354.37M$249.92M$132.00M$4.42M-$184.00K
    Research and development$189.59M$145.82M$76.06M$70.89M$30.37M$19.45M$69.59M$12.37M
    Operating income$208.47M$190.83M$192.03M$120.19M$87.53M$16.99M-$145.90M-$41.44M
    Net income$158.69M$145.49M$128.85M$181.47M$34.60M-$36.94M-$151.98M-$39.90M
    EBITDA$230.76M$213.04M$215.59M$144.97M$108.62M$26.56M-$142.10M-$41.26M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$268.92M$261.28M$215.39M$243.78M$239.46M$200.49M$184.73M$201.27M$186.04M$172.81M$154.62M$168.41M
    Gross profit$188.23M$198.08M$170.88M$175.23M$179.81M$162.34M$152.74M$146.86M$143.26M$140.67M$127.13M$125.26M
    Operating income$54.20M$89.32M$37.29M$38.56M$65.49M$48.18M$56.24M$55.73M$61.71M$21.36M$52.03M$40.20M
    Net income$48.20M$75.43M$32.49M$22.49M$50.87M$39.78M$45.56M$49.48M$46.09M$11.59M$38.33M$26.61M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $163.66M by $588.84M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$1.27B$999.20M$811.45M$673.87M$433.44M$427.07M$106.70M$89.28M
    Current assets$907.01M$579.25M$451.07M$400.29M$284.44M$262.89M$31.50M$86.68M
    Cash and equivalents$752.50M$453.00M$311.66M$243.78M$234.31M$228.63M$24.46M$83.52M
    Total liabilities$401.41M$340.05M$344.46M$271.03M$246.94M$329.89M$118.29M$7.75M
    Short-term debt$20.00M$16.25M$15.00M$2.00M$2.00M$0N/AN/A
    Long-term debt$143.66M$163.02M$178.57M$189.65M$189.98M$194.25M$97.95MN/A
    Shareholder equity$870.22M$659.15M$466.99M$402.84M$186.51M$97.18M-$422.86M$81.53M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.48B$1.37B$1.27B$1.27B$1.21B$1.11B$1.06B$999.20M$928.13M$858.38M$846.99M$811.45M
    Total liabilities$406.01M$373.84M$361.48M$401.41M$373.10M$334.93M$335.01M$340.05M$331.33M$319.80M$331.59M$344.46M
    Cash and equivalents$647.10M$549.77M$589.40M$752.50M$647.00M$546.05M$489.00M$453.00M$387.37M$317.30M$332.98M$311.66M
    Shareholder equity$1.07B$999.24M$910.35M$870.22M$835.12M$773.08M$720.52M$659.15M$596.80M$538.58M$515.39M$466.99M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow$348.20M$219.82M$219.39M$144.47M$98.56M-$2.98M-$75.44M-$38.80M
    Capital expenditures$310.00K$34.22M$37.28M$172.00K$298.00K$2.00K$149.00K$1.34M
    Free cash flow$347.89M$185.60M$182.11M$144.29M$98.26M-$2.99M-$75.58M-$40.14M
    Dividends paidN/AN/A$5.05MN/AN/A$200.30M$143.77MN/A
    Share repurchases$0$0$100.00M$0$300.00K$167.00K$0N/A
    Investing cash flow-$39.65M-$67.48M-$46.44M-$141.83M-$100.30M-$2.00M-$127.15M-$1.34M
    Financing cash flow-$9.05M-$11.00M-$105.55M$6.84M$7.42M$209.16M$143.77M$21.61M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$76.69M$92.43M$27.76M$126.15M$108.73M$79.33M$33.99M$75.56M$70.50M$42.62M$31.14M$76.67M
    Capital expendituresN/AN/A$0$107.00K$71.00K$4.00K$128.00K$33.58M$3.00K$632.00K$5.00K$37.07M
    Free cash flowN/AN/A$27.76M$126.04M$108.66M$79.32M$33.86M$41.98M$70.50M$41.98M$31.14M$39.59M
    Last 12 quarters

    Frequently Asked Questions About HRMY

    What is Harmony Biosciences Holdings' annual revenue?

    Harmony Biosciences Holdings reported revenue of $868.45M for the fiscal year ended Dec 31, 2025.

    How fast is Harmony Biosciences Holdings' revenue growing?

    Revenue was up 21.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 25.6%.

    Is Harmony Biosciences Holdings profitable?

    Yes. Harmony Biosciences Holdings reported net income of $158.69M for the fiscal year ended Dec 31, 2025, with a net margin of 18.3%.

    How much free cash flow does HRMY generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $348.20M minus capital expenditures of $310.00K produced free cash flow of $347.89M.

    How much debt does Harmony Biosciences Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $143.66M, short-term debt of $20.00M and cash and equivalents of $752.50M.